Positive Scientific Advice from the U.S. FDA for Planned Phase II …
KIEL, Germany I January 08, 2025 I tiakis Biotech AG, a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that the Company has received positive scientific advice from the U.S. FDA on a planned Phase II trial for the treatment of Pulmonary Arterial Hypertension (PAH).
Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 31, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free ...
Jan 11, 2025 · NEW YORK, NY. USA I January 10, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or ...
Oral semaglutide demonstrates a 14% reduction in risk of major …
Oct 21, 2024 · BAGSVAERD, Denmark I October 21, 2024 I Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE).
Metsera Secures $215 Million Series B Financing to Further …
Nov 13, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Pimicotinib Significantly Improved Outcomes for Patients with ...
Nov 12, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
All news - Pipelinereview
Jan 28, 2025 · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical ...
Oct 17, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab …
Dec 5, 2024 · BIZENGRI ® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic 1; Merus and Partner Therapeutics announced a license agreement for U.S. commercialization; UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I December 04, 2024 I Merus N.V. (Nasdaq: MRUS) [Merus, the Company ...